The ability of 23ME-01473 to activate NK cells and induce tumor growth control in vivo was evaluated using a humanized NSCLC PDX model that endogenously expresses cell surface ULBP6/2/5 and MICA/B (Fig. 6A and B) and produces sULBP6/2/5 (Fig. 6C). Here, RAET1L is linked to neoplasm.